JND003是一种新型选择性ERRα激动剂，可缓解非酒精性脂肪肝和胰岛素抵抗，PK和组织分布测定通过美迪西进行

JND003 is a potent and selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. JND003 is orally bioavailable and exhibits high grade of distribution in liver and abdominal adipose tissues. Pharmacokinetics (PK) and Tissue Distribution Assays of JND003 were performed at Medicilon.

Reference

Liufeng Mao, et al. Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance. ACS Bio Med Chem Au. 2022 Jun 15;2(3):282-296. doi: 10.1021/acsbiomedchemau.1c00050.